Document and entity information

Dec 2020

Jun 2020

Company information

Company information

FASF member mark

true

第1四半期決算短信

Document name

〔日本基準〕（連

結）

Filing date

2020-08-12

TAIKO

Company name

PHARMACEUTICAL

CO.,LTD.

Stock exchange listings

Tokyo

true

Tokyo 1st section

true

Tokyo 2nd section

-

Tokyo Mothers

-

Tokyo JASDAQ

-

Tokyo PRO Market

-

Tokyo Others

-

Nagoya

-

Nagoya 1st section

-

Nagoya 2nd section

-

Nagoya Centrex

-

Nagoya Others

-

Sapporo

-

Sapporo

-

Sapporo Ambitious

-

Sapporo Others

-

Fukuoka

-

Fukuoka

-

Fukuoka Q-Board

-

Fukuoka Others

-

Green Sheet

-

Japan Securities Dealers Association

-

Securities code

45740

URL

http://www.seirogan.c

o.jp

Business category

General Business

true

Specific Business

-

Fiscal Year End

2020-12-31

Quarterly period

1

Representative

Title

Name

Inquiries

Title

Name

Tel

Other

Quarterly statement filing date (as planned) Supplemental material of quarterly results Way of getting

Convening briefing of quarterly results Target for briefing of quarterly results

Note to fraction processing method

代表取締役社長

柴田 高

執行役員経営企画担

当

日高 幹夫

06-4391-1123

2020-08-12

true

-

-

-

（百万円未満切捨 て）

Business Results-Quarterly operating results

(in millions of yens)

Jun 2020

Jun 2019

Quarterly operating results

Quarterly operating results

Consolidated operating results

Consolidated income statements information

Net sales

Net sales

5,773

1,416

% change

-

11.9

Operating profit

Operating profit

2,757

180

% change

-

193.0

Ordinary profit

Ordinary profit

2,702

127

% change

-

347.2

Profit attributable to owners of parent

Profit attributable to owners of parent

1,870

103

% change

-

165.8

Note to consolidated income statements information

Comprehensive income

Comprehensive income

1,863

107

Change in comprehensive income

-

-

Other consolidated operating results

Basic earnings per share (Yen)

43.56

2.41

Diluted earnings per share (Yen)

43.28

2.40

Note to consolidated operating results

（注）１．当社は、

2020年４月１日付で

普通株式１株につき

３株の割合で株式分

割を行っております。

前連結会計年度の期

首に当該株式分割が

行われたと仮定して、

「１株当たり四半期

純利益」及び「潜在

株式調整後１株当た

り四半期純利益」を

算定しております。

２．当連結会計年度

は決算期変更の経過

Note to operating results

期間となり、当第１四

半期連結累計期間に

ついては、当社並びに ３月決算であった連 結子会社は３ヵ月 （2020年４月１日～ 2020年６月30日）、 12月決算の連結子会 社は６ヵ月（2020年 １月１日～2020年６ 月30日）を連結対象 期間とした変則決算 となっております。こ のため、対前年同四半 期増減率については 記載しておりません。

Business Results-Quarterly financial positions

(in millions of yens)

Jun 2020

Mar 2020

Quarterly financial positions

Quarterly financial positions

Consolidated financial positions

Total assets

27,205

25,473

Net assets

20,669

19,373

Capital adequacy ratio (%)

75.9

76.0

Note to consolidated financial positions

Owner'sequity

20,656

19,359

Note to financial positions

-

Business Results-Note to quarterly business results

Jun 2020

Quarterly note to business results

Quarterly note to business results

Note to consolidated financial results

Note to consolidated financial results

-

Quarterly Dividends

(in millions of yens)

Dec 2020

Jun 2020

Mar 2020

Quarterly dividends

Quarterly dividends

Dividends

Dividend per share (Yen)

Dividend per share (Yen)

First quarter

Result

-

-

Second quarter

Result

10.00

Forecast

7.00

Upper

-

Lower

-

Third quarter

Result

-

Forecast

-

Upper

-

Lower

-

Year end

Result

40.00

Forecast

10.00

Upper

-

Lower

-

Annual

Result

50.00

Forecast

17.00

Upper

-

Lower

-

Correction of dividend forecast from the most recent dividend forecast

Correction of dividend forecast from the most recent dividend forecast

Annual

-

Note to dividends

Note to dividends

当社は、2020年４月

１日付で普通株式１

株につき３株の割合

で株式分割を行って

Annual

おります。2020年３

月期については当該

株式分割前の実際の 配当金の額を記載し ております。

Quarterly Forecasts

(in millions of yens)

Dec 2020

Quarterly forecasts

Quarterly forecasts

3. 2020年12月期の連

Title for forecasts

結業績予想（2020年

４月１日～2020年12

月31日）

Preamble to consolidated forecasts

Preamble to forecasts

-

Main table of consolidated forecasts

Net sales

Net sales

Forecast

18,000

Upper

-

Lower

-

% change

Forecast

-

Upper

-

Lower

-

Operating profit

Operating profit

Forecast

5,500

Upper

-

Lower

-

% change

Forecast

-

Upper

-

Lower

-

Ordinary profit

Ordinary profit

Forecast

5,300

Upper

-

Lower

-

% change

Forecast

-

Upper

-

Lower

-

Profit attributable to owners of parent

Profit attributable to owners of parent

Forecast

3,800

Upper

-

Lower

-

% change

Forecast

-

Upper

-

Lower

-

Basic earnings per share (Yen)

Basic earnings per share (Yen)

Forecast

88.49

Upper

-

Lower

-

Note to consolidated forecasts

Note to forecasts

Correction of financial forecast from the most recent financial forecast Correction of financial forecast from the most recent financial forecast

Forecast

当連結会計年度は決 算期変更の経過期間 となり、通期について は、当社並びに３月決 算であった連結子会 社は９ヵ月間（2020 年４月１日～2020年 12月31日）、12月決 算の連結子会社は従 来通り12ヵ月間

（2020年１月１日～ 2020年12月31日）を 連結対象期間とした 変則決算となってお ります。このため、対 前期増減率について は記載しておりませ ん。連結業績予想の修 正については、本日 （2020年８月12日） 公表いたしました 「業績予想の修正に 関するお知らせ」を ご覧ください。

true

Notes, Quarterly-Material changes in subsidiaries during this period changes

in scope of consolidations resulting from change in subsidiaries

Jun 2020

Material changes in subsidiaries during this period (Changes in scope of consolidations resulting from change is subsidiaries)

Material changes in subsidiaries during this period (Changes in scope of consolidations resulting from change is subsidiaries)

Others

Material changes in subsidiaries during this period (Changes in scope of consolidations resulting from change is subsidiaries)

Material changes in subsidiaries during this period (Changes in

scope of consolidations resulting from change is subsidiaries)

Note to material changes in subsidiaries during this period

true

新規 １社 （社名） 台湾大幸薬品股分有 限公司除外 －社 （社 名） －（注）詳細 は、添付資料Ｐ．７ 「２．四半期連結財

務諸表及び主な注記

Note to material changes in subsidiaries during this period（３）四半期連結財 務諸表に関する注記 事項（当四半期連結 累計期間における重 要な子会社の異

動）」をご覧くださ い。

Notes, Quarterly-Applying of specific accounting of the consolidated quarterly

financial statements

Jun 2020

Applying of specific accounting of the consolidated quarterly financial statements

Applying of specific accounting of the consolidated quarterly financial statements

Others

Applying of specific accounting of the consolidated quarterly financial statements

Applying of specific accounting of the consolidated quarterly

financial statements

-

Note to applying of specific accounting of the consolidated quarterly financial statements

Note to applying of specific accounting of the consolidated

quarterly financial statements

-

Notes, Quarterly-Changes in accounting policies and accounting estimates

retrospective restatement

Jun 2020

Changes in accounting policies, accounting estimates and retrospective restatement

Changes in accounting policies, accounting estimates and retrospective restatement

Others

Changes in accounting policies, accounting estimates and retrospective restatement

Changes in accounting policies based on revisions of accounting

-

standard

Changes in accounting policies other than ones based on

-

revisions of accounting standard

Changes in accounting estimates

-

Retrospective restatement

-

Note to changes in accounting policies, accounting estimates and

retrospective restatement

Note to changes in accounting policies, accounting estimates and

-

retrospective restatement

Notes, Quarterly-Number of issued and outstanding shares common stock

Jun 2020

Mar 2020

Jun 2019

Number of issued and outstanding shares (common stock)

Number of issued and outstanding shares (common stock)

Others

Number of issued and outstanding shares (common stock)

Number of issued and outstanding shares at the end of fiscal year

43,712,400

43,701,900

(including treasury stock)

Number of treasury stock at the end of fiscal year

769,863

769,863

Average number of shares

42,942,537

42,851,437

Note to number of issued and outstanding shares (common stock)

（注）当社は、2020 年４月１日付で普通 株式１株につき３株 の割合で株式分割を 行っております。前連 結会計年度の期首に

Note to number of issued and outstanding shares (common stock) 当該株式分割が行わ れたと仮定して、「期 末発行済株式数」、 「期末自己株式数」 及び「期中平均株式 数」を算定しており ます。

This information is a summary of the earnings report. It does not contain all details included in the earnings report disclosed in Japanese.

Attachments

  • Original document
  • Permalink

Disclaimer

TAIKO Pharmaceutical Co. Ltd. published this content on 12 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2020 06:07:16 UTC